413 studies found for:    Waldenstrom
Show Display Options
Rank Status Study
1 Completed
Has Results
Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Perifosine
2 Active, not recruiting LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: LBH589
3 Completed Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Conditions: Waldenstrom's Macroglobulinemia;   Lymphoplasmacytic Lymphoma
Intervention: Drug: Bortezomib (Velcade)
4 Completed Sildenafil Citrate in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Sildenafil citrate (Viagra)
5 Completed CC-5013 and Rituximab in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: CC-5103;   Drug: Rituximab
6 Completed Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Thalidomide
7 Completed Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: BORTEZOMIB
8 Active, not recruiting Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
9 Recruiting An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia (WM)
Intervention: Drug: ACP-196
10 Terminated Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Intervention: Drug: Epratuzumab (hLL2- anti-CD22 humanized antibody)
11 Recruiting Ibrutinib With Rituximab in Previously Treated Adults With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
12 Recruiting Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: IMO-8400
13 Active, not recruiting Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Interventions: Drug: Everolimus;   Drug: Rituximab;   Drug: Bortezomib
14 Completed Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia
Conditions: Lymphoplasmacytic Lymphoma;   Waldenstrom's Macroglobulinemia
Intervention: Drug: Campath-1H
15 Unknown  Simvastatin in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: Simvastatin
16 Active, not recruiting
Has Results
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Condition: Waldenstrom Macroglobulinaemia
Intervention: Biological: Ofatumumab
17 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Conditions: Multiple Myeloma;   Waldenstrom's Macroglobulinemia;   Smoldering Multiple Myeloma;   Lymphoblastic Lymphoma
Intervention:
18 Recruiting Randomised Trial in Waldenstrom's Macroglobulinaemia
Condition: Waldenstrom's Macroglobulinaemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Biological: Rituximab;   Drug: Fludarabine
19 Completed A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Conditions: Waldenstrom's Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: Enzastaurin
20 Unknown  Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia
Conditions: Waldenström Macroglobulinemia;   Lymphoplasmacytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Drug: Chlorambucil;   Drug: Fludarabine

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years